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and sited at the University of Oxford (Jolley & Maiden 2010, BMC 
Bioinformatics, 11:595). The development of this site has been 
funded by the Wellcome Trust and European Union. This publica-
tion made use of the Meningitis Research Foundation Meningococ-
cus Genome Library (http://www.meningitis.org/research/genome) 
developed by Public Health England, the Wellcome Trust Sanger 
Institute and the University of Oxford as a collaboration. The pro-
ject is funded by Meningitis Research Foundation.
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Q FEVER CHRONIC OSTEOMYELITIS IN  
TWO CHILDREN
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Abstract: We report 2 cases of chronic Q fever osteomyelitis in 10- and 
5-year-old girls who presented with distal right femoral and left parasternal 
granulomatous osteomyelitis, respectively. Both were treated with cipro-
floxacin and rifampin with good response. Q fever osteomyelitis is a chal-
lenging diagnosis in children, and the choice of antimicrobial treatment is 
difficult because of limited available data.
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Q fever is a worldwide zoonosis caused by Coxiella burnetii, an obligate intracellular Gram-negative bacterium.1 In Portugal, 
Q fever has been described for more than 60 years, with manda-
tory reporting since 1999. This is an endemic disease mainly occur-
ring in the Central and Southern mainland region, with an average 
incidence of 0.08 cases per 100,000 inhabitants (2004–2008) and 
involving several C. burnetii genotypes.2
Infections are asymptomatic in 60% of the cases or pre-
sent as an acute self-limiting disease, usually characterized by 
flu-like symptoms, pneumonia and/or hepatitis.1,3 Progression to 
chronicity occurs in a small number of cases.1 Chronic Q fever 
forms include endocarditis, chronic vascular infections and more 
rarely, osteoarticular infection. In children, chronic Q fever is 
mostly unrecognized, and the antimicrobial regimen of choice is 
difficult because of limited information. We report 2 children with 
Q fever osteomyelitis who were successfully treated with rifampin 
and ciprofloxacin.
CASE 1
A 6-year-old, previously healthy, Caucasian girl presented 
in February 2012 with a 3-month history of right knee pain with 
no relief from analgesics. She reported minor local trauma and 
denied fever. She was born in Portugal and lived in a rural area 
of Lisbon with direct contact with farm animals (sheep and 
cattle). There was no history of consumption of unpasteurized 
milk. She was apyrexial, and her physical examination revealed 
moderate right knee soft-tissue swelling, with functional impair-
ment. There was no leukocytosis (8100/L) or increased inflam-
matory markers (C-reactive protein of 0.8 mg/L and erythrocyte 
sedimentation rate of 10 mm/h). A right distal end femoral lytic 
lesion was seen in a radiograph. The magnetic resonance imag-
ing showed metaphyseal hyperintensity on short tau inversion 
recovery sequences, with extension beyond the growth plate into 
the epiphysis (Fig. 1). Scintigraphy excluded multifocal involve-
ment. Histologic examination revealed noncaseating inflamma-
tory granulomas.
CASE 2
A 5-year-old, previous healthy, Caucasian girl, presented in 
January 2013 with a 2-week duration of left parasternal pain and 
swelling. She denied fever, and her physical examination was oth-
erwise normal. She lived in a rural area of Serpa with direct contact 
with cats, indirect contact with cattle and no history of ingestion 
of unpasteurized dairy products. The complete blood count and 
C-reactive protein were normal, but the erythrocyte sedimentation 
rate was elevated (40 mm/h).
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Magnetic resonance imaging revealed a 4-cm chondros-
ternal heterogeneous, hemorrhagic and partially necrotic mass on 
T2, with no other lesions shown on bone scintigraphy (see Fig., 
Supplemental Digital Content 1, http://links.lww.com/INF/C207). 
The histopathology showed a chronic necrotizing granulomatous 
inflammatory process.
In both cases, the findings of culture tests for bacteria and 
fungi, including mycobacteria, were negative. The findings of Man-
toux and serological tests for Borrelia burgdorferi, Bartonella spp. 
and Francisella tularensis were also negative. Elevated immunofluo-
rescence assay (IFA) antibody titers against C. burnetii phase I were 
present in both patients, suggesting potential chronic infections (labo-
ratory criteria: phase I: IgG ≥ 800; Case 1: phase I: IgG = 6400, IgM 
< 50, IgA = 200 and phase II: IgG = 6400, IgM < 50, IgA < 50; case 
2: phase I: IgG = 25,600, IgM < 50, IgA = 200 and phase II: IgG = 
400, IgM < 50, IgA < 50). Diagnosis was confirmed by C. burnetii 
DNA amplification on existing paraffin-embedded biopsies peformed 
during case investigation. For molecular testing, a TaqMan real time-
polymerase chain reaction (PCR) protocol, targeting the C. burnetii 
repetitive element IS1111, was used.5 Agent identity was confirmed 
by sequence determination and homology searches on GenBank 
database. Because of the lack of fresh biopsies, blood samples were 
additionally used for agent isolation attempts with negative results 
(also confirmed by PCR).
Echocardiogram ruled out endocarditis. Further immuno-
logic investigations including normal oxidative burst assessed by 
di-hydro-rhodamine, IL-12-INFγ pathway and lymphocyte count 
were normal for age. Antimicrobial therapy with rifampin (20 mg/
kg/bid) and ciprofloxacin (20 mg/kg/bid) was started and main-
tained for 18 months. A gradual clinical and serological improve-
ment was registered for case 1, and 6 months after the suspension 
of therapy, there was no recurrence of the disease, and antibody 
titers remained low (Table 1). In case 2, antibody titers decreased 
slowly, with a 4-fold reduction at 12 months. At 18-month follow-
up, despite the elevated phase I IgG titer of 1600 (8-fold decrease), 
there was no clinical evidence of disease, and treatment was dis-
continued. Three months later, no further recurrence of the disease 
was noted although the titers remained unchanged (Table 1).
DISCUSSION
Q fever osteomyelitis is a rare diagnosis, and to our knowl-
edge only 21 cases, 8 in children between 2 and 9 years old, have 
been reported.6,7
Because of its nonspecific clinical presentation, chronic 
Q fever is probably underestimated, and the majority of patients 
experience symptoms for a lengthy period before diagnosis.3 The 
range of osseous involvement is broad, from long to short bones. 
Single or multifocal involvement, with or without focal abscess 
collection, and sometimes multiple subcutaneous abscesses and 
fistulas have been described.7,8 Indeed in our patients the mild 
inflammatory markers and the unspecific clinical complaints, 
added to the low suspicion rate, deferred diagnosis. Also, in 
case 1 there was involvement of metaphysis and epiphysis, 
with growth plate commitment, and in case 2, there was a huge 
TABLE 1. Serological Evaluation by IFA of Anti-Coxiella burnetii Phase I and Phase II Antibodies in the 2 Pediatric 
Cases with Osteomyelitis
IFA Anti-C. burnetii Phase I/II Titers*
Initial 3 6 9 12 18 24 30 36 mo
Case 1
  IgG 6.400/6.400 3.200/400 3.200/200 1.600/200 800/− 400/− 400/− 200/− 200/−
  IgM −/− −/− −/− −/− −/− −/− −/− −/− −/−
  IgA 200/− 50/− 50/− 50/− 50/− 50/− 50/− −/− −/−
Case 2
  IgG 25.600/400 12.800/200 6.400/200 6.400/200 3.200/− 1.600/− 1.600/−
  IgM −/− −/− −/− −/− −/− −/− −/−
  IgA 200/− 100/− 50/− 50/− 50/− −/− −/−
− represents negative samples, according to IFA cutoff values: IgG < 200; IgM/IgA < 50. Bold values indicate positive IFA titers defined in a clinical compatible context as an 
evocative of chronic Q fever (phase I IgG ≥ 800).
*Expressed by the equivalent of the last dilution that gave positive results on indirect IFA, after testing the serum in sequential serial dilutions.
FIGURE 1. Osteolytic lesions on 
right distal femur and epiphysis 
(A) and chondrosternal region (B).
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PREDICTORS OF PERTUSSIS POLYMERASE CHAIN 
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2005–2009
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Abstract: Predictors of polymerase chain reaction (PCR) positivity for per-
tussis were assessed using Minnesota active surveillance data. Report of an 
exposure to pertussis and testing within the optimal time frame of ≤2 weeks 
were significantly associated with testing PCR positive, emphasizing the 
importance of asking about epidemiological factors when assessing patients 
for pertussis, and timely PCR testing.
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Pertussis incidence rates declined considerably in the US after the introduction of a pertussis vaccine in 1942; however, inci-
dence rates have been increasing since the 1980s.1 In Minnesota, 
rates of pertussis in outbreak years have exceeded 20 cases per 
100,000 population since 2004, which is nearly double the inci-
dence rate of outbreak years before 2004.2 This trend can be attrib-
uted, in part, to changes in vaccine formulation,3 evolution of 
the bacteria,4 and improved laboratory testing. Polymerase chain 
reaction (PCR) is commonly used to test for pertussis.5–8 PCR is 
more sensitive than culture and can detect nonviable bacteria5,6; 
however, similar to culture, PCR accuracy relies heavily on the 
timing of specimen collection.7,8 Using PCR during the first 2 
weeks of symptoms facilitates effective identification of pertussis, 
which can often be misdiagnosed as other upper respiratory tract 
infections.5,7,8 Although early detection and treatment of pertus-
sis is essential in reducing transmission and protecting high-risk 
contacts, maximizing the appropriate use of PCR testing must 
be considered. The aim of this study is to assess the clinical and 
epidemiologic factors associated with pertussis PCR positivity to 
inform judicious use of PCR testing.
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sternal infection, which was both very unusual and not previ-
ously described.
Chronic Q fever diagnosis usually relies on specific labo-
ratory testing with antibody detection using the standard indirect 
IFA. Yet, the optimal IFA cutoff value for phase I IgG is a matter 
of debate.4 Levels within the range of 800–1024 have been mostly 
accepted.4,9 However, Frankel et al10 have demonstrated that the 
positive predictive value of phase I IgG = 800 for proven chronic 
infection was only 37%. In children, the immune response after 
acute infection is very high, and titers up to 3200 have been dem-
onstrated without chronic infection.4 Given these data, Raoult et al4 
have proposed that for bone and joint Q fever infection a positive 
serological result should be confirmed by PCR or culture of the 
lesion.
Treatment of chronic Q fever has been much more diffi-
cult than that of acute disease.1 In adults, preferred treatment of 
endocarditis, the most frequent form of chronic infection, is well 
established, consisting of doxycycline and hydroxychloroquine 
for at least 18 months.6 Alkalinization of C. burnetti-containing 
vacuoles with chloroquine results in bacterial growth inhibition 
and improvement of doxycycline bactericidal activity. Indeed, 
this combination seems to reduce the treatment duration and the 
relapse rate to less than 5% in adults.1 In children, treatment of 
Q fever osteomyelitis is much more debatable, and few data are 
available.4,7
In children younger than 8 years, the doxycycline plus 
hydroxychloroquine combination should be used with caution 
because of the perceived risk of teeth discoloration, photosensivity 
and retinal toxicity.7 The long-term effectiveness of this regimen for 
osteomyelitis is also questioned.7
Alternatives are trimethoprim-sulfamethoxazole, ciproflox-
acin, rifampin and clarithromycin, but their efficacy is not proven. 
Rifampin and quinolones have been used with success in treatment. 
Given its high bone penetration and less side effects and based on 
previous pediatric case reports,3,7 ciprofloxacin plus rifampin was 
preferred by us, which was well tolerated, with only persistent 
cheilitis as a side effect in case 1.
Duration of antimicrobial treatment and follow-up should 
be guided by clinical and serological responses and may need to 
be maintained for long periods.1 The decrease in antibody titers is 
often delayed, with some patients maintaining markedly raised val-
ues for a long period, as noticed for case 2. After the first year of 
treatment, a 2-fold phase I IgG decrease is considered a favorable 
response, and a 4-fold decrease is usually indicative of cure.1 How-
ever, a phase I IgG < 800 is the most common accepted criterion to 
discontinue therapy, and it was accomplished in case 1. Given the 
high initial titer in case 2, we opted for a 4-fold decrease to stop 
treatment.
In conclusion, the treatment with a combination of cipro-
floxacin and rifampin may be effective for some cases of chronic 
Q fever osteomyelitis, but further reports are needed.
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